Catalent

Catalent provides integrated CDMO services including oral dose, biologics, specialty and clinical supply, as well as self-care products like OTC, dietary supplements and personal care. They offer technologies such as softgel, inhalation, cell and gene therapy, bioavailability enhancement, and small molecule injectable and oral manufacturing. Services span from early-stage design to commercial manufacturing (per Catalent website).

Catalent serves the pharmaceutical, biotech and self-care industries. Its pharma clients include innovators in biologics, gene therapy and small molecule drugs, while its self-care division partners with health and wellness brands for OTC, dietary supplement and personal care products (per Catalent website).

Catalent operates globally with a worldwide network of facilities. The firm's headquarters are in Somerset, New Jersey, and it has established operations in North America, Europe and Asia (per Catalent website).

Catalent does not publicly disclose its ownership structure or wealth origin. The firm is a publicly traded company on the New York Stock Exchange under the ticker CTLT (as of its last known filings), and its control or founding family is not disclosed on its public profile.

Catalent differentiates itself by offering end-to-end services for both pharmaceutical and self-care markets under one organization. It combines pharma-grade expertise with consumer product capabilities, covering regulated therapeutics and consumer health. The firm also highlights its advanced technologies in softgel, inhalation, and cell and gene therapy manufacturing (per Catalent website).